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Objectives:  Since  Exercise  and  Sports  Science  Australia  (ESSA)  first published  its position  statement  on
exercise  guidelines  for people  with  cancer,  there  has  been  exponential  growth  in research  evaluating  the
role of  exercise  pre-,  during  and  post-cancer  treatment.
Design  and  Methods:  The  purpose  of  this  report  is to use  the  current  scientific  evidence,  alongside  clin-
ical  experience  and  exercise  science  principles  to update  ESSA’s  position  statement  on  cancer-specific
exercise  prescription.
Results: Reported  in this  position  statement  is a  summary  of  the benefits  accrued through  exercise  follow-
ing  a  cancer  diagnosis  and  the  strengths  and  limitations  of this  evidence-base.  An  exercise  prescription
framework  is then  proposed  to  enable  the  application  of  cancer-specific  considerations  for  individu-
alisation,  specificity,  safety,  feasibility  and  progression  of exercise  for all patients.  Additional  specific
exercise  prescription  considerations  are  provided  for the  presence  of  haematological,  musculoskele-
tal,  systemic,  cardiovascular,  lymphatic,  gastrointestinal,  genitourinary  and  neurological  disease-  and
treatment-related  concerns,  as well  as  presence  of  co-morbid  chronic  disease.  Further,  we  also  identify
and  discuss  cancer-specific  pragmatic  issues  and  barriers  requiring  consideration  for  exercise prescrip-
tion.
Conclusions:  While  for the  majority,  multimodal,  moderate  to high  intensity  exercise  will  be  appropriate,
there  is no set  prescription  and  total  weekly  dosage  that  would  be  considered  evidence-based  for  all
cancer  patients.  Targeted  exercise  prescription,  which  includes  the  provision  of behaviour  change  advice
and support,  is needed  to  ensure  greatest  benefit  (as defined  by the  patient)  in the  short  and  longer  term,
with low  risk  of harm.
©  2019  Sports  Medicine  Australia.  Published  by Elsevier  Ltd.  This  is  an  open  access  article  under  the
CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Practical implications
• This document represents ESSA’s exercise and cancer position
statement and has the purpose of guiding individualised, targeted
exercise prescription to cancer patients through the application
of evidence, clinical experience and exercise principles.
• The exercise prescription that works best for whom and when
will be determined by patient assessment, identification and con-
sideration of general and cancer-specific health issues and their
contribution to risk of morbidity and/or mortality, and subse-
quent patient-driven goals.
• While for the majority, multimodal, moderate to high intensity
exercise will be appropriate, there is no set prescription and total
∗ Corresponding author.
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weekly dosage that would be considered evidence-based for all
cancer patients.
• Targeted exercise prescription, which includes the provision of
behaviour change advice and support, is needed to ensure great-
est benefit (as defined by the patient) is achieved in the short and
longer term, with very low risk of harm.
1. Introduction
In 2009, Exercise and Sports Science Australia (ESSA) pub-
lished its first position statement on optimising cancer outcomes
through exercise.1 Since that time, the position statement has been
used by health professionals to guide exercise prescription to can-
cer patients pre-, during and post-treatment, and has provided
the foundation for continuing education courses in upskilling the
workforce. In the past decade, cancer incidence in Australia has
increased and cancer survival has continued to improve,2 ensuring
https://doi.org/10.1016/j.jsams.2019.05.003
1440-2440/© 2019 Sports Medicine Australia. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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a rapidly expanding number of people living with a cancer diagnosis
(>400,000 Australians are currently living with a cancer diagno-
sis in the previous five years). Further, there has been exponential
growth in published high quality, randomised, controlled trials that
have evaluated the effect of exercise on a range of cancer-related
outcomes across the cancer trajectory, from diagnosis through to
end of life. In recognition that Accredited Exercise Physiologists
(AEPs) require and seek assistance in translating this evidence to
their exercise prescription practice for people with cancer, who
represent a growing population with diverse and cancer-specific
health needs and priorities, we present a new ESSA exercise and
cancer position statement. The purpose of this position statement
is to: (1) provide a contemporary overview of the exercise and
cancer evidence-base; and (2) present a framework for exercise
prescription to patients, with cancer-specific considerations for
individualisation, specificity, safety, feasibility and progression.
2. Evidence of exercise benefit following a cancer diagnosis
Benefits accrued through exercise during and beyond treat-
ment for cancer have been extensively reviewed. Specifically, a
recent publication reported that 140 meta-analyses have been
published to date, with the majority (75%) showing statistically
significant and clinically relevant benefit through exercise on
a range of treatment-related side effects, physical, functional,
and psychosocial outcomes.3 Our own review (date: 18/7/17;
search terms: ((“exercise”[MeSH Terms] OR “exercise”[All Fields])
AND (“neoplasms”[MeSH Terms] OR “neoplasms”[All Fields])) AND
(“2009”[PDAT] AND Review[ptyp])) identified more than 140
systematic reviews or meta-analyses and more than 90 non-
systematic reviews on new or emerging topics. There now exists
evidence of varying strength on the safety, feasibility and/or effi-
cacy of exercise throughout the cancer continuum in a range of
cancers, including but not limited to, more common cancers such
as breast,4 prostate,5 colorectal6 and lung7 cancer, as well as other
cancers including haematological,8 head and neck,9 cancers of
childhood and adolescence,10 and gynaecological cancers,11,12 and
less common cancers such as brain,13 testicular14 and pancreatic.15
Some studies have specifically targeted patient cohorts with more
advanced disease,16,17 providing initial evidence beyond patients
with early-stage disease, generally considered ‘well’.
Outcomes evaluated in trials have also broadened. There is now
trial evidence (again of varying strength) regarding the potential
positive effect of exercise for more contemporary treatment-
related side effects, such as chemotherapy-induced periph-
eral neuropathy,18 myalgia and arthralgias,19,20 lymphoedema
(upper- and lower-limb),21,22 bone health,23–25 sarcopenia26,27
and metabolic syndrome,28 sleep quality,29 cachexia,30 cognitive
impairment31 and cardiotoxicity,32,33 as well as outcomes partic-
ularly relevant to the clinical and public health setting, such as
treatment adherence or completion34–36 and cost-effectiveness.37
In the past five years, preliminary findings have also become avail-
able from phase 2 exploratory studies that have reported the effect
of exercise on survival outcomes.38–41
Despite the exponential growth in the number and quality
of clinical trials contributing to the broader evidence-base sup-
porting exercise in oncology, there remains a preponderance of
studies in the breast cancer setting and/or involving ‘healthier,
more active’ cancer patients,42 which is disproportionate to the
characteristics of the wider cancer population. Further, there are
varying levels of evidence in support of exercise as being safe,
feasible and effective for various cancer cohorts, cancer subtypes,
stages of disease and outcomes of interest. For example within the
breast cancer setting, there is strong evidence to support exercise
as being safe, feasible and effective at improving cardiorespira-
tory fitness, neuromuscular strength and quality of life during and
post-breast cancer treatment (particularly for those diagnosed with
early stage disease).43 In contrast, the evidence to support exercise
as being effective at improving survival outcomes for any cancer
cohort is weak (findings come from underpowered, exploratory
analyses).38–41 There is strong evidence that exercise leads to
benefits when integrated during active treatment for a range of
cancers,43 but no evidence to suggest that the specific timing of an
exercise session matters (e.g., evidence showing exercise during
chemotherapy infusion is more or less effective at improving sur-
vival outcomes versus before or after infusion is lacking). Following
a review of this literature, a forthcoming American College of Sports
Medicine publication (to be published in Medicine and Science in
Sports and Exercise, 2019) will provide exercise prescription guide-
lines specific to cancer-outcomes with a sufficient evidence-base
to do so. The ESSA exercise and cancer guideline update presents a
process that can guide the practical application of this evidence.
3. Recommended process for targeted, exercise
prescription for cancer patients
When the evidence base for all cancer types, cancer-specific out-
comes and different exercise prescriptions evaluated is reviewed in
light of its strengths and limitations and applied in practice along-
side generic exercise prescription principles, it provides a powerful
foundation from which exercise can be used to improve the lives
of those diagnosed with cancer. Fig. 1, represents a recommended
process that can guide individualised, evidence-based assessment,
exercise prescription and follow-up to cancer patients (defined
from herein as a person who  has been diagnosed with cancer). It
incorporates cancer-specific considerations to all aspects of patient
care, including assessment and initial exercise prescription, as well
as exercise principles of progressive overload, periodisation and
autoregulation. Further, it incorporates the use of behaviour change
strategies, education and monitoring, to ensure a patient-centred
approach to the provision of care (specificity), while enabling
patients to develop the necessary skills to ensure exercise can ben-
efit their health in the longer term. The process is as follows:
1) Patient assessment, including patient and family health his-
tory (presence of comorbidities/additional chronic disease and
related treatment); cancer diagnosis (previous and current);
cancer treatment (previous, current and planned); risk, presence
and severity of treatment-related toxicities (acute, persistent
and late side effects); and physical activity and exercise history.
2) Determine health issues and prioritise contribution of these to risk
of morbidity and/or mortality. Exercise prescription following
cancer diagnosis typically seeks to influence any one or more of
a range of outcomes, including but not limited to prevention or
management of disease- and treatment-related toxicities. The
exercise prescription must be focussed on ameliorating issues
with greatest impact on health and survival.
3) Identify patient capacity and intervention suitability determined
by considering economic, psychosocial and physiological con-
straints (including contraindications), accessibility, preferences,
self-efficacy, barriers and facilitators to exercise, and potential
benefit.
4) Prescribe exercise according to patient-driven exercise-related
goals.
5) Reassessment and prescription modification by following points
1–4.
Screening tools and guidelines, such as the ESSA Adult
Pre-Exercise Screening tool,44 Physical Activity Readiness
Questionnaire,45 or the American College of Sports Medicine
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Fig. 1. Recommended process for targeted exercise prescription for cancer patients.
(ACSM) guidelines for exercise testing and prescription46,47 are
useful for developing an initial health and risk profile for an
individual. However, these tools are not designed to collect the
necessary additional information required to enable safe and feasi-
ble exercise prescription for cancer patients. Instead, information
needs to be collected on all issues specified in point 1 above, most of
which can be sourced directly from the patient. However, patient-
derived information, particularly with respect to risk of developing
acute, persistent or late treatment-related side effects, needs to be
supplemented with information derived from reputable sources.
The Australian Government online resource of cancer treatment
protocols (https://www.eviq.org.au) may  be useful in this regard.
This information (point 1 above)  could be supplemented with
questionnaires typically used in cancer research and clinical
management to measure and track changes in patient-reported
outcomes including quality of life (e.g., Functional Assessment of
Cancer Therapy (FACT) – General,48 Patient-reported Outcomes
Measurement Information System (PROMIS)49), treatment-related
side effects (e.g., PROMIS,49 FACT-Breast50) and exercise self-
efficacy.51 The initial assessment could also include a battery
of physical/functional tests including assessments (or surrogate
measures) of cardiorespiratory fitness, function, strength, balance,
body composition and bone health.
Responses to screening tools, AEP-derived template of ques-
tions, externally-sourced treatment-related information, patient-
completed questionnaires, and results from physical assessment
will allow an AEP and cancer patient to discuss point 2 above,
and can aid the clinical judgement as to whether further test-
ing, medical investigation or medical clearance is needed prior
to commencing an exercise program. While there is no ‘correct’
or ‘optimal’ number and type of patient-reported or objectively-
measured outcomes included in an initial assessment, patient test
burden must be considered and limited. What must be measured
are the minimum parameters necessary to prescribe a safe, feasible
and effective exercise program. The inclusion of additional assess-
ments should only occur when benefit of the information collected
outweighs the burden of its assessment. Overall, research findings
can only suggest potential components of the initial assessment; in
the end, clinical judgement that is based on the patient’s circum-
stances and exercise-related goals will dictate what is (and is not)
assessed and why.
For a patient in the active treatment phase,52 it is best prac-
tice to contact the treating clinician, informing them that exercise
prescription is being integrated into cancer care and providing
opportunity for comment or concerns. During treatment, the most
appropriate clinician to liaise with will depend on the type and
stage of cancer and treatment being received. For example, a urol-
ogist, medical oncologist or radiation oncologist may be the most
appropriate clinician for those receiving treatment for prostate
cancer, chemotherapy for colorectal cancer or radiation therapy
for head and neck cancer, respectively. A general practitioner
will likely be the most relevant clinician to liaise with during
the post-treatment survivorship phase. Discussions with a patient
during the initial assessment (point 1 above) will allow an AEP
to identify the most appropriate clinician to communicate with
and to establish consent to discuss patient information with this
clinician.
The need for medical clearance prior to exercise testing and pre-
scription for cancer patients is a topic of debate. Endorsing a blanket
requirement for medical clearance for all cancer patients creates an
additional barrier to the provision of exercise prescription.53 Fur-
ther, given the known harm of inactivity, only in rare circumstances
would a targeted, exercise prescription be contraindicated. Yet the
potential benefits of targeted exercise prescription prior, during
and post-cancer treatment may  not be recognised by all treating
clinicians and may contribute to a situation whereby those patients
most in need are the least likely to receive medical clearance (i.e.,
AEPs receive medical clearance and subsequent referral for only the
‘well’ cancer patient). However, requesting medical clearance can
instigate communication between the AEP and a treating clinician,
and the subsequent transfer of relevant exercise considerations
that a patient may  or may  not be aware of. Therefore, the need
for medical clearance should be considered on a case by case basis,
but direct communication with at least one member of the treating
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team who can provide clinical guidance when needed53 is recom-
mended for all patients.
Following initial assessment (point 1 above), the next task is
to assist a cancer patient to identify their specific health (psycho-
logical and/or physiological), quality of life and survival concerns
(point 2 above) and to discuss potential benefit through exer-
cise. Goals of exercise need to be prioritised according to what
is of most value to the patient (e.g., symptom management,
improving mood, minimising declines in cardiorespiratory fitness,
reversing loss of muscle mass, survival), noting that some may
prioritise long-term over short-term goals, psychosocial benefits
over physiological or functional benefits, and that goals and pri-
orities for all will likely change over time. A targeted exercise
prescription is one that seeks to achieve these goals. Patient-factors
that may  influence adherence to this targeted prescription then
need to be identified and discussed (point 3 above). This includes
understanding patient circumstances (including current functional
capacity, physical limitations/constraints) and preferences pertain-
ing to type, frequency, intensity and duration, available finances
to support exercise participation (which will influence degree
to which the exercise is supervised and where), health literacy,
exercise self-efficacy, ability to identify and problem solve exercise-
related barriers (which may  be cancer-specific or general), the
support network available to assist integrating exercise during and
beyond cancer management, and motivation to achieve goals via
exercise.
It will also be necessary to educate the patient about what
constitutes realistic exercise-related goals (e.g., maintenance of
function, slowing declines or improvements in function), with the
patient’s current cancer survivorship phase (pre-, during, post-
treatment with treatment aim being cure, substantive remission
or palliation52) influencing expectations. Further, educating the
patient about what exercise components will be necessary for
achieving specific goals, particularly when patient exercise pref-
erences fail to align with achieving their desired goal(s), will be
relevant and important. In these instances, an AEP will need to
help guide the patient in recognising what they are willing to do
to achieve a goal (even if not enjoyable) versus what they are not
willing to do. The final exercise prescription (point 4 above) repre-
sents one that considers exercise goals alongside health priorities,
and ensures the patient is central to the discussion and decisions
made.
Frequency and components of reassessment and prescription
modification (point 5 above) will be influenced by the exercise pre-
scription goals, whether the patient is in an active treatment phase,
likelihood of changes in disease- and treatment-related toxicities
that may  influence or be influenced by the exercise prescription
and access to AEP services. Of note, when the process of targeted
exercise prescription is followed, AEPs can readily identify when
a patient may  benefit from referral to another allied health pro-
fessional. For example, referral to a dietitian for those in need of
nutritional advice, referral to supportive services (e.g., peer support
connections) and health professionals including a psychologist,
specialist oncology nurse or counsellor for those reporting concerns
with fear of recurrence, or referral to a physiotherapist for those
with acute or persistent musculoskeletal or neurological issues.
Further, an AEP may  play a pivotal role in referring a patient back
to the treating team for clinical review of new or changing disease-
and treatment-related toxicities or side effects, which may  or may
not be associated with progression of disease.
While it is not possible to provide a specific exercise prescrip-
tion based on an individual’s diagnosis (and likely never will be),
there are some general exercise prescription guidelines that will
be appropriate for the majority of cancer patients, including chil-
dren through to geriatric patients (Table 1). Also, the growing body
of evidence suggests beneficial prescription parameters for a num-
ber of side effects and treatment-related outcomes (Table 2). In
some cases, it will be appropriate to look to other disease states
or chronic conditions for exercise principles and guidelines tar-
geting similar outcomes (e.g., exercise and obesity guidelines for
obese women receiving treatment for endometrial cancer; exer-
cise and osteoporosis guidelines for osteopenic women receiving
aromatase inhibitors for breast cancer or men  receiving androgen
deprivation therapy for prostate cancer; Table 2). However, appro-
priate caution is necessary given that the generalisability of safety,
feasibility and efficacy findings among comorbidities is unknown.
Further, as the benefits of exercise following cancer are better elu-
cidated, it is prudent for exercise professionals to remain cognisant
of potential harm through exercise, to educate patients about, and
monitor presence of, contraindications, which largely relate to the
presence of new or unusual changes to existing signs and symp-
toms (Table 2). Our approach of placing strong emphasis on using
changes in signs and symptoms to guide exercise prescription (and
exercise prescription modifications), while continuing to acknowl-
edge the relative risks associated with abnormal haematological or
other markers (e.g., oxygen saturation levels at rest), when known,
is similar to that recently suggested by others.54
3.1. Core components of exercise prescription: mode, intensity,
frequency, duration, total exercise dosage, progression,
periodisation and autoregulation
Exercise mode: A multimodal exercise program, comprising aer-
obic and resistance (targeting large and specific muscle groups)
exercise should be included in a patient’s exercise prescription
(Table 1). However, the focus or emphasis of aerobic versus resis-
tance exercise must be determined by a patient’s needs and goals.
For example, a woman with endometrial cancer advised to lose
weight through dietary change, will need to increase emphasis on
resistance training to ensure preservation of lean tissue during peri-
ods of weight loss, whereas a lung cancer patient who needs to
improve cardiorespiratory fitness will need to increase emphasis
on aerobic exercise. Exercise prescription emphasis requirements
based on specific considerations are presented in Table 2. While
there is cross-over in exercise benefit (i.e., resistance exercise can
produce a cardiorespiratory adaptation and aerobic exercise can
produce a neuromuscular strength and endurance adaptation in
cancer patients55,56), the magnitude of benefit will be influenced
by training specificity.56 As such, it is appropriate to consider
patient preferences and resources when prescribing exercise mode,
particularly during the early stages of exercise prescription in
deconditioned patients. However, a patient also needs to be edu-
cated with respect to optimal exercise mode for achieving their
defined exercise goals. Further, the specific modes chosen within
aerobic and resistance exercise (e.g., water-based exercise versus
use of ergometers versus walking, or free-weights versus machine-
weights versus therabands) should be influenced by cancer-specific
factors (Table 2), as well as patient preferences.
The inclusion of balance and flexibility training may  improve the
ability to undertake daily activities with reduced falls risk, discom-
fort, pain or concerns.57 Yoga and Tai chi, which have been shown
to improve quality of life and other cancer-related outcomes58–60
(Table 2), are potentially time efficient and beneficial means for
incorporating balance training into exercise prescription for those
in need. The inclusion of pelvic floor exercises is also particularly
important for patients with or at high-risk of urinary and faecal
incontinence (such as those treated for genitourinary, colorectal
or gynaecological cancers), but likely appropriate for the majority
of adult and geriatric patients.61 Further, for highly decondi-
tioned patients or patients nearing end of life, exercise prescription
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Table  1
Foundation exercise prescription guidelines for cancer patients.
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emphasis may  need to be placed on ‘mobility’ exercises (e.g., a
range of specific upper- and lower-body exercises undertaken with
low/no load) to accommodate and progress (when relevant) car-
diovascular and respiratory function, neuromuscular strength and
endurance, and flexibility capabilities.
While focus should be given to targeted exercise prescription
to address priority health issues, any kind of activity that a patient
considers enjoyable or perceives as positively influencing cancer-
related outcomes (e.g., pain, quality of life) should be permitted
or even encouraged. These activities (e.g., low-intensity yoga, Tai
chi, meditation) can supplement the exercise prescription and will
enhance adherence while providing additional physiological and
psychological benefit. The exception to this recommendation is
when a specific activity is considered contraindicated or risk of
harm outweighs benefit (e.g., a brain cancer patient with bal-
ance concerns who wants to keep road cycling, a paediatric cancer
patient with thrombocytopenia who wants to continue playing
competitive rugby, an osteoporotic breast cancer patient who  is
taking aromatase inhibitors and wants to only do water-based exer-
cise). When this is the case, patient education around benefit versus
risk, and revisiting short and long term goals and priorities may
help in steering the patient towards safe, feasible and effective
exercise (e.g., advising use of a road bike on a wind-trainer for the
brain cancer patient, encouraging participation in certain compo-
nents of training but not game play for the paediatric cancer patient
with thrombocytopenia; doing two water-based sessions per week,
supplemented with two land-based strength sessions, including
appropriate impact loading, per week for the osteoporotic breast
cancer patient).
Intensity: Patients should not be restricted to low-intensity exer-
cise, nor is high-intensity exercise contraindicated for all. However,
there will be times when low-intensity exercise is recommended
(e.g., a patient with nausea that worsens with moderate inten-
sity exercise) and when high intensity exercise may  need to be
avoided (e.g., immediate weeks post-surgery to avoid adversely
influencing wound healing; presence of a blood clot related to
a peripherally-inserted central catheter). Helping patients under-
stand what constitutes low, moderate and high intensity exercise
through the use of one or more tools, including rating of per-
ceived exertion scale, heart rate and repetition maximum, is
recommended. Self-reported methods of assessing intensity are
considered particularly useful for those at risk of their heart rate
response being influenced by treatment-induced cardiac changes
or certain treatments (e.g., specific chemotherapeutic agents or
HER2 targeting drugs). Self-reported methods are also considered
useful for those experiencing ‘good’ and ‘bad’ days/weeks during
an active treatment period. Further, helping patients understand
what constitutes a normal physiological response to exercise and
that they are in the best position to measure and monitor exer-
tion (either by rating perceived exertion with or without objective
measurement of heart rate) may  improve exercise self-efficacy.62
The intensity of exercise sessions, including whether interval
training, impact loading, explosive dynamic training or other, is
included should be determined by patient-driven factors (short and
long term goals and interests) and cancer-specific factors (indica-
tions and contraindications, see Table 2). Evidence to support for
example, high intensity interval training over moderate intensity
continuous duration training for improving cardiorespiratory fit-
ness in the longer term in cancer patients is currently unclear.6,63
However, for a patient who needs to improve fitness in a spe-
cific and short time frame (e.g., lung cancer patient with only 4
weeks prior to surgery),64 there may  need to be greater emphasis
on undertaking exercise at high intensity.
Frequency and duration: Duration of any given exercise session
will influence frequency of exercise bouts per day or week. For
deconditioned patients, immediately post-surgery and/or for those
with advanced stage disease, a starting exercise prescription may
need to involve multiple short bouts (5–10 min  duration) daily, to
accumulate at least 20 min  on any given day. As exercise capacity
improves, progression towards longer sessions of at least 20 min
duration on most days of the week is recommended. The 20 min
cut-point being proposed (which has also been suggested by oth-
ers previously65) is not distinct and less duration per day may
be more optimal for some patients (e.g., palliative patients with
lung cancer). Instead this suggested cut-point reflects a pragmatic
exercise duration whereby there is sufficient time for an exercise
prescription that allows for a warm-up and cool-down component,
sufficient disruption to cardiovascular, respiratory, neuromuscu-
lar, endocrine and immune homeostasis, and requires patients to
actively plan/schedule their exercise, which in turn will aid longer
term positive behaviour change.66 Further, sessions of a minimum
of 20-min duration could allow for sufficient weekly exercise dose
while incorporating rest days (noting that rest days may  be pur-
posely scheduled into the exercise prescription due to pragmatic
reasons or preferences, or be unplanned and occur due to the pres-
ence of one or more barriers).
Total exercise dosage: Intensity, frequency and duration com-
bine to produce total dosage of exercise prescription over a defined
period (e.g., week or month). Information gathered during the ini-
tial assessment, with particular attention to current and previous
exercise, will enable an AEP to determine the appropriate starting
exercise dosage. Erring on the side of caution (that is, prescribe less
than more) in the initial phases of an exercise program, particularly
for sedentary or deconditioned patients is recommended. Note, the
targets promoted in physical activity guidelines for cancer patients
(that is, >150 min  of moderate intensity aerobic activity/>75 min
of vigorous intensity aerobic activity plus 2 resistance exercise
sessions, per week67) may  not represent an appropriate starting
weekly exercise dosage for the majority of cancer patients, nor
may  they ever be achievable for specific patients. Studies involv-
ing women  with either ovarian or metastatic breast cancer, and
patients with either lung or pancreatic cancer, have specifically
shown that while some may be able to achieve physical activity
targets through exercise prescription at least some of the time, oth-
ers were never able to achieve the target during the intervention
period assessed.30,68,69 Further, for some, the target may  be unnec-
essary for accruing benefit (that is, benefits have been observed
with lower dosages).63
It will be important for patients to have an understanding of
what constitutes their ideal weekly exercise dosage, and whether
there is need for this dosage to be modified over time. The known
dose-response relationship between exercise and physical and psy-
chosocial outcomes is relevant for patients with cancer. Evidence
from a large, systematic review of cohort studies evaluating the
association between physical activity post-cancer and survival out-
comes suggest that a weekly exercise dosage of around 150 min
of moderate intensity (or equivalent volume) exercise per week
represents the approximate dosage beyond which there may  be
diminishing benefits gained through undertaking higher dosages.70
Nonetheless, there is some evidence to suggest that exercising
at higher dosages may  contribute to additional benefit in spe-
cific outcomes (e.g., fitness) for specific cohorts (e.g., patients with
colon cancer).71 While future research continues to improve our
understanding about what constitutes minimum and maximum
exercise dosage thresholds and for whom,  it is reasonable to suggest
that the majority of cancer survivors can safely undertake regu-
lar exercise, when commenced at conservative dosages, progressed
gradually and appropriately modified for the presence of disease-
and treatment-related side effects and co-morbidities (Table 2).
There is potential for benefit in the translation of research
into periodisation to exercise prescription for cancer patients and
several exercise oncology trials have incorporated various periodi-
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sation models.25,72 Variation in volume and intensity across the
week or within treatment cycles may  stimulate greater physio-
logical adaptation, and reduce boredom and risk of over-training.
Further, periodised plans designed for optimal preparation for spe-
cific events, such as surgery or commencement of chemotherapy or
radiation therapy, or to specifically address particular health issues
should be considered. This may  include sequential and cycling
phases of emphasis on specific exercise modes such as resistance,
aerobic, balance, and impact training. For example, the prescrip-
tion of an extended phase of heavy resistance training before
progressing to impact loading for maintaining bone density25;
planned emphasis on low intensity exercise when treatment-
related symptoms are severe, and high intensity exercise when
symptoms are mild; or emphasis on high load resistance train-
ing with water-based aerobic exercise during the initial weeks of
exercise prescription for obese patients (Table 2).
In recognition that cancer patients experience marked fluctua-
tions in exercise tolerance, capacity and self-efficacy, particularly
during the active treatment phase, it is paramount to ensure flexi-
bility is built into the exercise prescription. The prescription should
enable patients to autoregulate session, weekly and monthly exer-
cise dosage to accommodate ‘good days/weeks’ (whereby higher
intensity and/or dosage may  be undertaken) and ‘bad days/weeks’
(whereby reduced intensity and/or total dosage may  be required to
accommodate symptoms). Autoregulation can occur, when neces-
sary, through modifications to mode, intensity, frequency, duration
and/or total volume, guided by objective (e.g., heart rate, rep-
etitions completed) and/or subjective (e.g., rating of perceived
exertion) measures. Examples of the implementation of autoreg-
ulation in the oncology setting have been previously published
for aerobic73 and resistance74 exercise. Overall, the total exercise
dosage for a defined period should seek to achieve the desired
physical and mental health benefit(s), while balancing risks of over-
training, maladaptation, suboptimal, low priority or unnecessary
exercise.
Progression: How to approach the progression of exercise pre-
scription will differ depending on whether the patient is in the
pre-, during or post-treatment cancer survivorship phase.52 For
example, physical and physiological declines are typically observed
during active treatment periods, and also during periods of disease
progression. Consequently, an exercise intensity that is moder-
ate in the early weeks of treatment may  elicit a physiological
response indicative of vigorous intensity exercise in the final weeks
of chemotherapy or when the disease has advanced. As such,
minimising regression of total exercise dosage and relative inten-
sity, or maintaining these parameters throughout the treatment
period could be considered appropriate progression and incorpo-
rates patient autoregulation as discussed above.
For those who have completed treatment with a curative
intent, it is generally reasonable to expect that exercise can be
progressed steadily through increased overall dosage via mod-
ifications to mode, frequency, intensity and duration. However,
it remains important to consider the influence of any persis-
tent treatment-related toxicities or co-morbidities and the risk
of new issues, as well as the potential challenge of returning to
daily activities including work, on how progression should and
could be defined. For example, returning to domestic chores, paid
employment, volunteering or family responsibilities after treat-
ment, while maintaining previous weekly exercise dosage could be
considered appropriate progression in the first 3–6 months post-
treatment.
In all cases, the goal of progression is to facilitate and main-
tain benefits derived through exercise prescription in the short and
longer term. Those who are already meeting or exceeding public
health physical activity guidelines or conversely, those who  are
sedentary at time of diagnosis, may  require more assistance with
understanding what appropriate progression means and how it
can be defined. For example, helping regular exercisers to modify
expectations around physical response to exercise and to appre-
ciate that minimising declines in function during active treatment
periods is indicative of exercise benefit. For those who are sedentary
at diagnosis, helping them to overcome fears associated with ‘doing
too much’ and learning differences between treatment-related side
effects and normal, short term physiological responses to exercise
overload, will likely be an important part of provision of exercise
prescription and support. However, it will also be necessary to help
patients avoid overtraining, which may bring with it higher risk of
physical stress, injury, and compromised immune function, with
unknown effect on key cancer-outcomes, such as quality of life,
treatment tolerance and effectiveness, and even survival. Signs of
overtraining would include the presence of unusual symptoms,
increased severity of symptoms and changes in symptom trajec-
tory (e.g., persist longer than expected). Overall, a key role of an
AEP is to assess the safety, feasibility and effect of specific exer-
cises, weekly dosage and pace of progression within the framework
of an individual cancer patient’s risk profile and exercise-related
goals.
3.2. Behaviour change strategies — an important component of
exercise prescription
Through the implementation of behaviour change techniques
including goal setting, self-monitoring, individualised education,
exercise prescription and feedback, and social support, exercise
adherence can be improved.75 This, in turn, facilitates achiev-
ing predefined exercise goals. Identifying and helping a patient
problem-solve general and cancer-specific issues and barriers to
exercise also forms an essential component of exercise prescrip-
tion (Table 3). Finally, incorporating behaviour change strategies as
part of the routine provision of exercise prescription will improve
patient exercise self-efficacy,76 and as such, provide them with the
tools to use exercise to benefit their longer term health.
Education and monitoring of exercise prescription: In addition to
standard exercise-related education topics, including appropriate
clothing and footwear, hydration, and safe and appropriate use of
equipment, a patient needs to be equipped to monitor the pres-
ence and severity of treatment-related side effects before, during
and following exercise sessions and to be able to report on exer-
cise response to the AEP. This represents important information
that will enable appropriate modification to exercise prescription
parameters for the purpose of autoregulation, periodisation and
progression. Further, this information also allows for an adverse
event or contraindication to exercise to be readily identified and
managed accordingly. The presence of an unusual symptom or
an unusual change to an existing symptom, rather than the pres-
ence of a persistent treatment-related side effect or symptom in
itself, is more likely to represent an exercise contraindication. To
detect the ‘unusual’, it is first necessary to have a clear under-
standing of what constitutes ‘normal’ or ‘expected’ for any given
patient.
4. Conclusion
Overall, evidence supports that the implementation of exercise
prescription brings with it reduced morbidity, improved function
and quality of life, and potential for improved survival, with very
low risk of harm. However, the strength of the evidence in support
of exercise safety, feasibility and benefit is dependent on cancer
type and outcome of interest. While for the majority, multimodal,
moderate to high intensity exercise will be appropriate, there is no
set prescription and total weekly dosage that would be considered
1198 S.C. Hayes et al. / Journal of Science and Medicine in Sport 22 (2019) 1175–1199
evidence-based for all cancer patients. Appropriate exercise pre-
scription for cancer patients needs to be targeted and individualised
according to patient- and cancer-specific considerations.
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